These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1805065)

  • 1. [Evaluation of the hemodynamic effects of the long-acting peripheral vasodilator flosequinan in patients with chronic heart failure].
    Abdurakhmanov US; Naumov VG; Shevliagin SA; Novikov SV; Mareev VIu; Belenkov IuN
    Kardiologiia; 1991 Nov; 31(11):49-51. PubMed ID: 1805065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
    Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
    J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
    Kessler PD; Packer M; Medina N; Yushak M
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
    Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
    J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure.
    Bartels GL; Remme WJ; Look MP; Kruijssen DA
    J Card Fail; 1995 Mar; 1(2):117-25. PubMed ID: 9420641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure.
    Isnard R; Lechat P; Pousset F; Carayon A; Kalotka H; Chikr H; Salloum J; Thomas D; Komajda M
    Fundam Clin Pharmacol; 1997; 11(1):83-9. PubMed ID: 9182081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flosequinan in chronic heart failure: how is exercise capacity improved?
    Banning AP; Ramsey MW; Jones EA; Evans W; Carolan G; Jones CH; Henderson AH
    Eur J Clin Pharmacol; 1996; 51(2):133-8. PubMed ID: 8911877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and long-term effects of flosequinan in patients with chronic cardiac failure.
    Marchionni N; Moschi G; Di Bari M; Burgisser C; Fumagalli S; Boncinelli L; Tarantini F; Ferrucci L
    Am Heart J; 1993 Jul; 126(1):147-54. PubMed ID: 8322657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction.
    Schneeweiss A; Wynne RD; Marmor A
    Jpn Heart J; 1989 Sep; 30(5):627-34. PubMed ID: 2614925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flosequinan induces hemodynamic improvement in heart failure complicating acute myocardial infarction.
    Schneeweiss A; Marmor A; Wynne RD
    Herz; 1988 Aug; 13(4):259-62. PubMed ID: 3169679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.
    Falotico R; Haertlein BJ; Lakas-Weiss CS; Salata JJ; Tobia AJ
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):412-8. PubMed ID: 2476620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure.
    Bartels GL; Remme WJ; Wiesfeld AC; Kok FJ; Look MP; Krauss XH; Kruyssen HA
    Cardiovasc Drugs Ther; 1990 Jun; 4(3):705-12. PubMed ID: 2076381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic vasodilator therapy with flosequinan in congestive heart failure.
    Haas GJ; Binkley PE; Leier CV
    Clin Cardiol; 1990 Jun; 13(6):414-20. PubMed ID: 2188766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.
    Cowley AJ; Wynne RD; Stainer K; Fullwood L; Rowley JM; Hampton JR
    BMJ; 1988 Jul; 297(6642):169-73. PubMed ID: 3044507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure.
    Markus H; Cowley AJ
    Eur J Clin Pharmacol; 1991; 40(6):535-8. PubMed ID: 1884731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of flosequinan in patients with heart failure of acute onset complicating acute myocardial infarction.
    Schneeweiss A; Wynne RD; Marmor A
    Int J Cardiol; 1989 Jul; 24(1):73-6. PubMed ID: 2668206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A non-invasive evaluation of flosequinan on haemodynamics and exercise capacity in chronic congestive heart failure.
    Motro M; Freimark D; Feinberg MS; Wynne RD; King C; Schneeweiss A
    Int J Clin Pharmacol Res; 1993; 13(3):143-9. PubMed ID: 8225697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure.
    Burstein S; Semigran MJ; Dec GW; Boucher CA; Fifer MA
    J Am Coll Cardiol; 1992 Oct; 20(4):822-9. PubMed ID: 1527293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of flosequinan on exercise capacity and symptoms in severe heart failure.
    Elborn JS; Stanford CF; Nicholls DP
    Br Heart J; 1989 Apr; 61(4):331-5. PubMed ID: 2653391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of flosequinan, given over 3 days, evaluated by continuous hemodynamic monitoring.
    Schneeweiss A; Plich M; Green T; Wynne RD; Marmor A
    Cardiology; 1989; 76(3):201-5. PubMed ID: 2776141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.